Page 1

R IRLAB IRLAB THERAPEUTICS AB ( PUBL ) Q3 Interim report July - September " The license agreement with Ipsen is a milestone for IRLAB - our business model is validated and our scalable research platform ISP provides the conditions to increase the pace in our value creation . " 2021